Holen Sie sich die Stockscreener-App
114.22
1.41%
1.59
Handel nachbörslich:
111.53
-2.69
-2.36%
Schlusskurs vom Vortag:
$112.63
Offen:
$112.54
24-Stunden-Volumen:
851.30K
Relative Volume:
1.19
Marktkapitalisierung:
$5.52B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-177.04M
KGV:
-30.16
EPS:
-3.7867
Netto-Cashflow:
$-153.53M
1W Leistung:
+5.50%
1M Leistung:
-0.68%
6M Leistung:
+138.93%
1J Leistung:
+1,220%
1-Tages-Spanne:
$112.54
$115.08
1-Wochen-Bereich:
$109.20
$117.91
52-Wochen-Spanne:
$7.575
$120.31
Celcuity Inc Stock (CELC) Company Profile
Firmenname
Celcuity Inc
Sektor
Branche
Telefon
763-392-0767
Adresse
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
114.22 | 5.44B | 0 | -177.04M | -153.53M | -3.7867 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-12 | Eingeleitet | Wells Fargo | Overweight |
| 2025-11-18 | Eingeleitet | Wolfe Research | Outperform |
| 2025-11-17 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-09-22 | Eingeleitet | Guggenheim | Buy |
| 2025-07-01 | Fortgesetzt | Stifel | Buy |
| 2024-07-22 | Eingeleitet | Leerink Partners | Outperform |
| 2024-02-22 | Eingeleitet | Stifel | Buy |
| 2023-12-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-09-07 | Eingeleitet | Jefferies | Buy |
| 2021-07-29 | Eingeleitet | Cowen | Outperform |
| 2021-07-27 | Eingeleitet | Needham | Buy |
| 2021-01-28 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-11 | Fortgesetzt | Craig Hallum | Buy |
| 2018-11-20 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Celcuity Inc Aktie (CELC) Neueste Nachrichten
Celcuity Inc. (CELC) interactive stock chart - Yahoo Finance Singapore
Is Celcuity (CELC) Still Attractive After Its Strong One Year Share Price Rally - Yahoo Finance
Celcuity Inc. (NASDAQ:CELC) Q4 2025 earnings call transcript - MSN
CELC Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Richard Buller Sells 3,000 Shares of Celcuity (NASDAQ:CELC) Stock - marketbeat.com
Celcuity at TD Cowen Conference: Strategic Insights on Gedatolisib - Investing.com
Celcuity outlines potential $2.5B annual peak revenue for gedatolisib amid pivotal clinical milestones and commercial launch preparations - MSN
Celcuity (CELC) 10K Form and Latest SEC Filings 2026 - MarketBeat
CELC PE Ratio & Valuation, Is CELC Overvalued - Intellectia AI
Aug Update: Can Celcuity Inc ride the EV waveEarnings Growth Summary & Verified Technical Trade Signals - baoquankhu1.vn
Baker Bros. Advisors LP Increases Stake in Celcuity Inc. - GuruFocus
Aug Big Picture: Is Celcuity Inc stock a smart retirement pickMarket Trend Review & Entry Point Confirmation Signals - baoquankhu1.vn
Hennion & Walsh Asset Management Inc. Acquires 19,579 Shares of Celcuity, Inc. $CELC - MarketBeat
Tudor Investment Corp ET AL Invests $1.35 Million in Celcuity, Inc. $CELC - MarketBeat
HC Wainwright Increases Earnings Estimates for Celcuity - marketbeat.com
Why Celcuity Stock Popped Today - aol.com
Assessing Celcuity (CELC) Valuation After FDA Priority Review And Commercial Launch Preparations - simplywall.st
Liquidity Mapping Around (CELC) Price Events - Stock Traders Daily
LifeSci Capital Maintains Celcuity(CELC.US) With Buy Rating, Maintains Target Price $125 - Moomoo
Celcuity (NASDAQ:CELC) Upgraded to Hold at Wall Street Zen - MarketBeat
H.C. Wainwright reiterates Celcuity stock rating at neutral By Investing.com - Investing.com India
Celcuity Inc. (NASDAQ:CELC) Q4 2025 Earnings Call Transcript - Insider Monkey
H.C. Wainwright reiterates Celcuity stock rating at neutral - Investing.com
1290 VT Micro Cap Portfolio's Celcuity Inc(CELC) Holding History - GuruFocus
Why Celcuity stock popped today - MSN
Celcuity’s Earnings Call: Big Data, Bigger Ambitions - TipRanks
Why Celcuity Stock Popped Today - The Motley Fool
Stifel Raises Price Target for Celcuity (CELC) to $125, Maintains Buy Rating | CELC Stock News - GuruFocus
Trade Recap: Will Celcuity Inc stock recover after earningsQuarterly Trade Review & Daily Volume Surge Signals - baoquankhu1.vn
Celcuity Inc. 2025 Annual Report: Clinical-Stage Biotech Advancing Gedatolisib for Breast Cancer Treatment - minichart.com.sg
Stifel raises Celcuity stock price target to $125 on trial timing By Investing.com - Investing.com India
Stifel raises Celcuity stock price target to $125 on trial timing - Investing.com India
Craig-Hallum raises Celcuity stock price target to $141 on NDA progress By Investing.com - za.investing.com
Craig-Hallum raises Celcuity stock price target to $141 on NDA progress - Investing.com
Celcuity (NASDAQ:CELC) Price Target Raised to $125.00 - MarketBeat
Celcuity's (CELC) "Buy" Rating Reiterated at Needham & Company LLC - marketbeat.com
Celcuity Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Celcuity 10-K: $0 Revenue, $(3.79) EPS; $177M Net Loss - TradingView
Celcuity (NASDAQ: CELC) highlights pivotal gedatolisib trials and FDA Priority Review - Stock Titan
Celcuity Inc (CELC) Q4 2025 Earnings Call Highlights: Navigating Losses Amidst Promising Drug ... By GuruFocus - Investing.com Canada
Celcuity Q4 2025 Earnings Call Transcript - MarketBeat
TD Cowen Maintains Celcuity(CELC.US) With Buy Rating - Moomoo
Celcuity Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Celcuity Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Transcript : Celcuity Inc., Q4 2025 Earnings Call, Mar 25, 2026 - marketscreener.com
Celcuity Q4 Earnings Call Highlights - MarketBeat
CELC: FDA priority review, strong trial data, and robust cash position set stage for 2026 launch - TradingView
Earnings call transcript: Celcuity beats Q4 2025 EPS forecast, stock rises - Investing.com
Finanzdaten der Celcuity Inc-Aktie (CELC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):